SGMS1 and central nervous system cancer: These novel findings show the opposing roles of these two SMS isoforms in GBM cells and glioma patients, and that the antitumor drug 2OHOA, which has demonstrated safety and efficacy in phase I/IIA clinical trial, can differentially modulate SMS1, a potential new anticancer drug target.